Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Overview of attention for article published in Infectious Diseases and Therapy, October 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#9 of 1,075)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 15 news outlets
policy: 2 policy sources
twitter: 223 X users
patent: 3 patents

facebook: 1 Facebook page
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 296 Mendeley

So far, Altmetric has seen 18 news stories from 15 outlets.

Sophisticated natural products as antibiotics - Nature - Alert Breaking News - United States

Alert Breaking News - US, 31 Jul 2024

Lewis, K. The science of antibiotic discovery. Cell 181, 29–45 (2020). CAS PubMed Google Scholar Tacconelli, E.

Antimicrobial prescribing: meropenem with vaborbactam

National Institute of Health and Care Excellence , 20 Nov 2019

Key messages The content of this evidence review was up-to-date in November 2019.

15 Dicembre 2018 | The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

Padova News, 15 Dec 2018

– The Menarini Group has recently reached an agreement with Melinta Therapeutics to commercialize meropenem/vaborbactam in…

News story from Finanz Nachrichten on Wednesday 12 December 2018

Finanz Nachrichten, 12 Dec 2018

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 14 additional news stories.